How do we curate the results of NGS-based genomic profiles? How do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability?

How do we curate the results of NGS-based genomic profiles? How do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability?

How do we curate the results of NGS-based genomic profiles? In particular, how do we prioritize subsidiary molecular markers, especially when there are multiple drivers identified, and determine their level of actionability? Is there a systematic approach to this clinical challenge?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lia Tsimberidou, MD, PhD

Lia Tsimberidou, MD, PhD

Tenured Associate Professor
Department of Investigational Cancer Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX